Key Highlights

  • Revenue was USD 1,624.9 million against an estimate of USD 1.60 billion; diluted EPS was USD 0.31 against USD 0.23.
  • Net income attributable to the company was USD 44.5 million, compared with a net loss of USD 23.5 million.
  • Adjusted EBITDA was USD 138 million, and the 2026 range is now USD 500 million to USD 535 million.
  • Cash and cash equivalents were USD 766 million at September 30, against total Debt of USD 1.1 billion.

Ardent Health (NYSE:ARDT) reported third quarter Revenue of USD 1,624.9 million, against USD 1,576.7 million a year earlier and an estimate of USD 1.60 billion. The hospital operator posted diluted EPS of USD 0.31 against an estimate of USD 0.23, compared with a loss of USD 0.17 per share in the third quarter of 2025. President and CEO Dave Caspers described the quarter as one of improving performance, with volumes improving sequentially.

Revenue and Volumes

Adjusted admissions increased 2.9% to 91,933, which followed a 2.5% increase in the second quarter. Admissions were 41,899 against 41,862, a 0.1% increase after a 1.0% decline in the second quarter. Emergency room visits were 163,909, up 1.7% from 161,198.

Surgical volumes were lower. Total surgeries were 31,934 against 32,545, a 1.9% decrease, with inpatient surgeries down 5.0% and outpatient surgeries down 0.6%. Net patient service revenue per adjusted admission was USD 17,370 against USD 17,252.

Profit and Margins

Net income attributable to Ardent Health was USD 44.5 million, or USD 0.31 per diluted share, against a net loss of USD 23.5 million. Adjusted EBITDA was USD 138 million and adjusted EBITDAR was USD 180 million, both non-GAAP measures. The company tied adjusted EBITDA to its IMPACT program initiatives, improving Volume trends and operational execution.

Cost lines moved in different directions. Salaries and benefits were USD 647.9 million against USD 677.0 million, which the CEO described as a 4% reduction in salaries, wages and benefits expense. Other operating expenses were USD 162.8 million against USD 198.7 million. The CEO said IMPACT initiatives remain aimed at achieving at least USD 70 million of savings this year.

Cash, Balance Sheet and Guidance

Operating cash flow was USD 122 million in the quarter and USD 258 million for the first nine months, against USD 247 million a year earlier. Total debt was USD 1.1 billion, the net Leverage Ratio was 0.8x and lease-adjusted net leverage was 2.5x, with available Liquidity of USD 1 billion. The company repurchased 1.0 million shares for USD 11 million in the quarter, and its board added USD 25 million to the repurchase program, leaving about USD 48 million of authorization.

During the quarter, Ardent signed a definitive agreement to transition full ownership of its Kansas hospital to its joint venture partner. The CEO said the transaction is aimed at enhancing margins and redeploying Capital in core markets.

The 2026 adjusted EBITDA range moved to USD 500 million to USD 535 million from USD 485 million to USD 535 million, which the CEO described as a 1.5% increase at the midpoint. Revenue guidance of USD 6,400 million to USD 6,700 million was maintained. Net Income attributable to the company is guided at USD 132 million to USD 167 million, diluted EPS at USD 0.93 to USD 1.18 and adjusted admissions growth at 1.5% to 2.5%.

Data Points to Watch

Revenue of USD 1,624.9 million sits alongside adjusted EBITDA of USD 138 million, Operating Cash Flow of USD 122 million and cash of USD 766 million.

Management named the savings target of at least USD 70 million from IMPACT initiatives this year, the 2026 guidance ranges and the Kansas hospital ownership transition as items in focus. It also named adjusted admissions growth of 1.5% to 2.5% and rent expense payable to REITs of USD 168 million as guidance components.